In Section C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will receive treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. Ubiquitin-related proteins that control the stability of key Tremendous enhancer-mediated proteins https://kinkyn888dpa1.bloggactivo.com/profile